

**THERAVECTYS is invited to participate in the symposium the Institut Pasteur is holding for the 30 years of research on the AIDS virus
“30 years of HIV Science: Imagine the future Symposium”**

THERAVECTYS' paper is entitled “Perfection and clinical evaluation of a new anti-HIV therapeutic vaccine based on lentiviral vectors”

Paris, May 20, 2013

THERAVECTYS, a French biotechnology company that is developing a new generation of vaccines, announces that it has been selected by the Scientific Council of the Institut Pasteur to participate in the symposium devoted to the 30 years of research on the AIDS virus.

Cécile BAUCHE, the company's Scientific Director, says, *“We are currently conducting the clinical testing of an anti-HIV therapeutic vaccine based on a new vaccine approach using lentivectors. We are delighted with the Institut Pasteur's invitation, which emphasizes the quality of our research and the interest aroused by our new generation of vaccines. This innovative technology is not limited to HIV and can find applications on many other indications.”*

About the AIDS epidemic

The AIDS epidemic was identified thirty years ago, in 1981. For lack of any treatment, the first ten years of dealing with it emphasized prevention. The second decade made it possible to develop anti-viruses that could stabilise this mortal illness.

Over the last ten years, the objective was to make it possible for the greatest number of patients to gain access to these medicines, including patients living in developing countries. A special accent was placed on facilitating the conditions of administering the treatments and trying to reduce the secondary effects. This devastating pandemic has laid 30 million dead in 30 years. According to the UNAIDS 2012 report on the worldwide AIDS epidemic, 1.7 million people throughout the world have died from the consequences of AIDS and 2.5 million were newly infected in 2011. At the end of 2011, 34 million people had caught the AIDS virus worldwide, 23.5 million of whom are in Sub-Saharan Africa.

About the available treatments

Anti-retroviral medicines are used in the treatment and prevention of infection by HIV. These combat the virus by limiting its proliferation in the body. More than 30 different medicines exist today, broken down mainly into three classes: Nucleoside reverse transcriptase inhibitors, non-nucleoside inhibitors and pro-

tease inhibitors. An association with a medicine of each class is usually prescribed (tritherapy).

According to UNAIDS 2012, more than 8 million people contaminated by HIV were benefitting from an anti-retroviral therapy in low- and intermediate-income countries at the end of 2011. This has brought a 24% decrease in mortality, especially in Sub-Sahara Africa, the geographic zone most affected by the pandemic.

The current treatments available against HIV are constrictive, costly and exhibit serious secondary effects for the patient. They do not heal the illness but only slow down the advance of the infection, as long as they are taken regularly and without interruption. Current polytherapies against HIV only partially meet the problem situation of the virus' hypervariability and the associated escape mechanism. It is all the more important to propose therapeutic alternatives as resistance to this type of treatment is beginning to appear.

An alternative to existing treatments: therapeutic vaccines

THERAVECTYS is currently conducting a clinical test of therapeutic anti-HIV vaccination. This vaccine should allow the patient to temporarily and perhaps even definitively stop all treatment. For this, we are using the original technology of lentiviral vectors.

Contrary to other gene transfer vectors, these new-generation vectors have the unique capacity to induce a strong, sustainable and diversified cellular immune response that should allow the elimination of the infected cells.

About THERAVECTYS

THERAVECTYS, a biotechnologies company, is developing a new generation of vaccines based on the technology of lentiviral vectors, stemming from fundamental research work conducted at Institut Pasteur.

This breakthrough technology should make it possible to effectively prevent or treat many pathologies against which the induction of an effective cellular immune response is necessary: viral illnesses (HIV), bacterial or parasitic illnesses, cancers, etc.

Since its creation, THERAVECTYS has been working on the perfection of a therapeutic anti-HIV

vaccine for which the clinical test of phase I/II is in progress.

On the basis of an exclusive worldwide license with Institut Pasteur and with the financial support of government authorities (OSEO, ANR), THERAVECTYS is continuing its research and development efforts to fight other pathologies.

Alone or in collaboration with other pharmaceutical laboratories, THERAVECTYS is planning to engage soon in the development of new candidate vaccines.

For more information:

+33 1 43 90 19 20 - contact@theravectys.com

